![](http://images.investorshub.advfn.com/images/uploads/2015/6/15/cii%5BnPBIO.png)
Suggested Workflow to Accelerate the Discovery of New
Biomarkers for Early Diagnosis and Prediction of Complications
in Diabetes Includes Pressure BioSciences Novel PCT
Platform
Publication by Chinese and Swiss Researchers Discusses the
Importance of Identifying New Protein Biomarkers to
Significantly Improve Clinical Management of Diabetes
South Easton, MA -- July 13, 2015 -- InvestorsHub NewsWire
-- Pressure BioSciences, Inc. (OTCQB:
PBIO) (PBI and the Company), a leader in the development and
sale of broadly enabling, pressure cycling technology (PCT)-based
sample preparation solutions to the worldwide life sciences
industry, today announced the publication of an article in the
internationally recognized journal Biochimica et Biophysica Acta.
In the article, the authors reviewed the current status of
biomarker discovery in diabetes mellitus (diabetes) and provided
insights into the need for, limitations, and possible solutions for
biomarker discovery and validation in the field of diabetes
research. The authors were Dr. Shiying Shao of the Tongji Hospital,
Huazhong University of Science and Technology (Wuhan, PR China) and
Drs. Tiannan Guo and Ruedi Aebersold of the Institute of Molecular
Systems Biology, ETH Zurich (Zurich, Switzerland).
Diabetes is a common metabolic disorder that currently affects
several hundred million people worldwide. It is estimated that the
number of individuals with diabetes could increase to approximately
366 million by 2030. Unfortunately, even with advances resulting
from diabetes research over the past few decades, a number of
significant clinical issues remain for the diabetic patient,
including renal, retinal, and neurological complications. Thus, the
discovery of new biomarkers for the early diagnosis, progression,
and underlying pathway dysfunction of diabetes is vital to help
improve clinical outcome.
Dr. Shiying Shao, lead author of the review article, commented:
Prediction and early detection of diabetes offer the potential to
delay or even reverse the diabetic process. Unfortunately,
currently available diagnostic markers fail to achieve these goals.
Thus, it is imperative to identify new biomarkers that offer
physicians the ability to evaluate both the necessity and course of
medical intervention.
Professor Ruedi Aebersold, co-author of the review article,
said: PCT is a promising sample preparation technology that permits
the fast and robust preparation of protein samples from minute
amounts of specimen with minimal technical variation. Mass
spectrometry (MS)-based proteomics, such as the SWATH-MS system we
developed jointly with AB Sciex, stands out as a promising new
approach that can be used to explore and potentially discover and
validate novel diabetic protein biomarkers.
Dr. Tiannan Guo, co-author of the review article, said: MS-based
proteomics is evolving rapidly. Although it has penetrated into
many branches of biomedical research, obsolete methods still
frequently appear in diabetes research literature. We believe that
a workflow that combines PCT sample preparation with SWATH-MS next
generation proteomics (PCT-SWATH) may offer vastly improved
reproducibility, sensitivity, and proteome coverage to the diabetes
research field.
Mr. Richard T. Schumacher, President and CEO of PBI, stated: The
incidence of diabetes is increasing at an alarming rate worldwide.
Together with the authors of this review article, we believe that
current diagnostic markers for early diagnosis and progression to
complications in diabetes are inadequate, and that new, next
generation methods for the discovery and validation of such
biomarkers are needed. We look forward to working with the authors,
their colleagues, and other researchers around the world, in the
development and expansion of the PCT-SWATH workflow in the
important field of diabetes research.
About the Review Article
Mass spectrometry-based proteomic quest for diabetes
biomarkers.
Shiying Shao, Tiannan Guo, Ruedi Aebersold.
Biochim Biophys Acta. 2015 Jun;1854(6):519-527. doi:
10.1016/j.bbapap.2014.12.012.
PMID: 25556002
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (PBI) (OTCQB: PBIO) develops,
markets, and sells proprietary laboratory instrumentation and
associated consumables to the estimated $6 billion life sciences
sample preparation market. Our products are based on the unique
properties of both constant (i.e., static) and alternating (i.e.,
pressure cycling technology, or PCT) hydrostatic pressure. PCT is a
patented enabling technology platform that uses alternating cycles
of hydrostatic pressure between ambient and ultra-high levels to
safely and reproducibly control bio-molecular interactions. To
date, we have installed over 250 PCT systems in approximately 160
sites worldwide. There are over 100 publications citing the
advantages of the PCT platform over competitive methods, many from
key opinion leaders. Our primary application development and sales
efforts are in the biomarker discovery and forensics areas.
Customers also use our products in other areas, such as drug
discovery & design, bio-therapeutics characterization, soil
& plant biology, vaccine development, histology, and forensic
applications.
Forward Looking Statements
Statements contained in this press release regarding PBI's
intentions, hopes, beliefs, expectations, or predictions of the
future are "forward-looking'' statements within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements
are based upon the Company's current expectations, forecasts, and
assumptions that are subject to risks, uncertainties, and other
factors that could cause actual outcomes and results to differ
materially from those indicated by these forward-looking
statements. These risks, uncertainties, and other factors include,
but are not limited to, the risks and uncertainties discussed under
the heading "Risk Factors" in the Company's Annual Report on Form
10-K for the year ended December 31, 2014, and other reports filed
by the Company from time to time with the SEC. The Company
undertakes no obligation to update any of the information included
in this release, except as otherwise required by law.
Investor Contacts:
Richard T. Schumacher, President & CEO Pressure BioSciences,
Inc.
Nathan P. Lawrence, Ph.D. VP of Marketing and Sales (508)
230-1828 (T)
For more information about PBI and this press release, please
click on the following website link:
http://www.pressurebiosciences.com
twitter
|
LinkedIn
|
YouTube |Google+
|
Facebook